Factors associated with the onset and survival of subsequent primary breast cancer in female non-metastatic breast cancer survivors

Abstract

This study aimed to investigate the risk factors for the onset of subsequent primary breast cancer (SPBC) in women with a previous diagnosis of early-stage breast cancer (BC) and to construct a prognostic prediction model for patients with SPBC. Using the Surveillance, Epidemiology, and End Results-17 (SEER-17) database, we conducted a retrospective cohort analysis on women with initial primary early-stage BC from 2004 to 2015. Standardized incidence ratio (SIR) was calculated to determine the risk of subsequent primary cancer (SPC). A competing risk model was built to identify the risk factors for the onset of SPBC. And risk factors associated with breast cancer-specific mortality in SPBC patients were evaluated and presented in the form of nomogram. Compared with the general population, the overall risk of SPC for all sites was significantly elevated in women with early-stage BC (SIR = 1.21, 95% CI: 1.20–1.23), and breast is the most frequent site. Age, race and ethnicity, year of diagnosis, history of other tumors, histological type, surgery, radiation, chemotherapy, tumor size, positive lymph nodes numbers and ER status were independent risk factors (p < .05) for the onset of SPBC. A new prognosis nomogram demonstrated good discrimination after internal validation with a C-index of 0.869 (95% CI: 0.859–0.880), and showed favorable consistency and clinical usefulness. The incidence of SPBC and prognosis of patients with SPBC were well estimated based on a large cohort. Our nomogram model had excellent prediction performance and could be a useful tool to predict prognosis.

References

[1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33.

[2] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

[3] Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363-385.

[4] Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9(6):606-616.

[5] Ahmad A. Breast cancer statistics: recent trends. Adv Exp Med Biol. 2019;1152:1-7.

[6] Mellemkjaer L, Friis S, Olsen JH, et al. Risk of second cancer among women with breast cancer. Int J Cancer. 2006;118(9):2285-2292.

[7] Molina-Montes E, Requena M, Sánchez-Cantalejo E, et al. Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis. Gynecol Oncol. 2015;136(1):158-171.

[8] Grantzau T, Overgaard J. Risk of second non-breast cancer among patients treated with and without postoperative radiotherapy for primary breast cancer: a systematic review and meta-analysis of population-based studies including 522,739 patients. Radiother Oncol. 2016;121(3):402-413.

[9] Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev. 2007;16(3):566-571.

[10] Wei JL, Jiang YZ, Shao ZM. Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study. Int J Clin Oncol. 2019;24(8):934-940.

[11] Raymond JS, Hogue CJ. Multiple primary tumours in women following breast cancer, 1973-2000. Br J Cancer. 2006;94(11):1745-1750.

[12] Knight JA, Fan J, Malone KE, et al. Alcohol consumption and cigarette smoking in combination: a predictor of contralateral breast cancer risk in the WECARE study. Int J Cancer. 2017;141(5):916-924.

[13] Reiner AS, Lynch CF, Sisti JS, et al. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. Breast Cancer Res. 2017;19(1):83.

[14] Reiner AS, Sisti J, John EM, et al. Breast cancer family history and contralateral breast cancer risk in young women: an update from the women's environmental cancer and radiation epidemiology study. J Clin Oncol. 2018;36(15):1513-1520.

[15] Watt GP, Knight JA, Lin C, et al. Mammographic texture features associated with contralateral breast cancer in the WECARE study. NPJ Breast Cancer. 2021;7(1):146.

[16] Kim BK, Oh SJ, Song JY, et al. Clinical characteristics and prognosis associated with multiple primary cancers in breast cancer patients. J Breast Cancer. 2018;21(1):62-69.

[17] Katuwal S, Jousilahti P, Pukkala E. Causes of death among women with breast cancer: a follow-up study of 50 481 women with breast cancer in Finland. Int J Cancer. 2021;149:839-845.

[18] Balachandran VP, Gonen M, Smith JJ, Dematteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173-e180.

[19] Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME. The surveillance, epidemiology, and end results (SEER) program and pathology: toward strengthening the critical relationship. Am J Surg Pathol. 2016;40(12):e94-e102.

[20] Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Br J Surg. 2015;102(3):148-158.

[21] Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res. 2007;13(2 Pt 1):559-565.

[22] Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant. 2010;45(9):1388-1395.

[23] Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res. 2012;18(8):2301-2308.

[24] Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133(6):601-609.

[25] Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364-1370.

[26] Alba AC, Agoritsas T, Walsh M, et al. Discrimination and calibration of clinical prediction models: users' guides to the medical literature. JAMA. 2017;318(14):1377-1384.

[27] Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565-574.

[28] Van Calster B, Wynants L, Verbeek J, et al. Reporting and interpreting decision curve analysis: a guide for investigators. Eur Urol. 2018;74(6):796-804.

[29] Desantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439-448.

[30] Soerjomataram I, Coebergh JW. Epidemiology of multiple primary cancers. Methods Mol Biol. 2009;471:85-105.

[31] Brenner H, Siegle S, Stegmaier C, Ziegler H. Second primary neoplasms following breast cancer in Saarland, Germany, 1968–1987. Eur J Cancer. 1993;29(10):1410-1414.

[32] Evans HS, Lewis CM, Robinson D, Bell CM, Møller H, Hodgson SV. Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in Southeast England. Br J Cancer. 2001;84(3):435-440.

[33] Ricceri F, Fasanelli F, Giraudo MT, et al. Risk of second primary malignancies in women with breast cancer: results from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 2015;137(4):940-948.

[34] Levi F, Te VC, Randimbison L, La Vecchia C. Cancer risk in women with previous breast cancer. Ann Oncol. 2003;14(1):71-73.

[35] Schaapveld M, Visser O, Louwman MJ, et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol. 2008;26(8):1239-1246.

[36] Molina-Montes E, Pollán M, Payer T, Molina E, Dávila-Arias C, Sánchez MJ. Risk of second primary cancer among women with breast cancer: a population-based study in Granada (Spain). Gynecol Oncol. 2013;130(2):340-345.

[37] Li Z, Wang K, Shi Y, Zhang X, Wen J. Incidence of second primary malignancy after breast cancer and related risk factors-is breast-conserving surgery safe? A nested case-control study. Int J Cancer. 2020;146(2):352-362.

[38] Lee J, Park S, Kim S, et al. Characteristics and survival of breast cancer patients with multiple synchronous or metachronous primary cancers. Yonsei Med J. 2015;56(5):1213-1220.

[39] Vanderwalde AM, Hurria A. Second malignancies among elderly survivors of cancer. Oncologist. 2011;16(11):1572-1581.

[40] Varghese F, Wong J. Breast cancer in the elderly. Surg Clin North Am. 2018;98(4):819-833.

[41] Malik MK, Tartter PI, Belfer R. Undertreated breast cancer in the elderly. J Cancer Epidemiol. 2013;2013:893104.

[42] Prochazka M, Hall P, Granath F, Czene K. Family history of breast cancer and young age at diagnosis of breast cancer increase risk of second primary malignancies in women: a population-based cohort study. Br J Cancer. 2006;95(9):1291-1295.

[43] Lee KD, Chen SC, Chan CH, et al. Increased risk for second primary malignancies in women with breast cancer diagnosed at young age: a population-based study in Taiwan. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2647-2655.

[44] Easton DF. Familial risks of breast cancer. Breast Cancer Res. 2002;4(5):179-181.

[45] King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-646.

[46] Berrington DGA, Curtis RE, Kry SF, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011;12(4):353-360.

[47] Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259-1271.

[48] Brown LM, Chen BE, Pfeiffer RM, et al. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat. 2007;106(3):439-451.

[49] Travis LB, Wahnefried WD, Allan JM, Wood ME, Ng AK. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol. 2013;10(5):289-301.

[50] Noone AM, Lund JL, Mariotto A, et al. Comparison of SEER treatment data with Medicare claims. Med Care. 2016;54(9):e55-e64.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Precision Medical Sciences published by John Wiley & Sons Australia, Ltd on behalf of Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital.